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Abstract The glutamate N-methyl-D-aspartate (NMDA) re-
ceptor antagonist ketamine (KET) produces rapid and sustained
antidepressant effects in patients. Tiletamine (TIL; 2-
ethylamino-2-thiophen-2-yl-cyclohexan-1-one) is another un-
competitive NMDA receptor antagonist, used in a medical
(veterinary) setting as an anesthetic tranquilizer. Here, we com-
pared the behavioral actions of KET and TIL in a variety of
tests, focusing on antidepressant-like and dissociative-like ef-
fects in mice and rats. The minimum effective doses of KET
and TIL were 10 mg/kg to reduce mouse forced swim test
immobility and 15 mg/kg to reduce marble-burying behavior.
However, at similar doses, both compounds diminished loco-
motor activity and disturbed learning processes in the mouse
passive avoidance test and the rat novel object recognition test.
KET and TIL also reduced social behavior and accompanying
50-kHz Bhappy^ ultrasonic vocalizations (USVs) in rats. TIL
(5–15 mg/kg) displayed additional anxiolytic-like effects in the
four-plate test. Neither KET nor TIL affected pain response in
the hot plate test. Examination of the Bside effects^ revealed
that only at the highest doses investigated did both compounds
produce motor deficits in the rotarod test in mice. While KET
produced behavioral effects at doses comparable between
species, in the rats, TIL was ~10 times more potent than in
the mice. In summary, antidepressant-like properties of both
KET and TIL are similar, as are their adverse effect liabilities.
We suggest that TIL could be an alternative to KET as an
antidepressant with an additional anxiolytic-like profile.
Keywords Ketamine . Tiletamine . Antidepressant-like
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Introduction
The rapid and sustained antidepressant effects of ketamine
(KET) (Zarate et al. 2006a; Berman et al. 2000) belong to
the most intriguing discoveries and most often discussed
topics in the current pharmacotherapy of major depression
disorder (MDD). However, the mechanism of this unique ac-
tion remains controversial and unexplained (Schatzberg
2014). KET acts primarily as a use-dependent antagonist at
glutamate NMDA receptors (NMDARs; for a broader panel
of other CNS targets, see Salat et al. (2015c)); thus, among
several mechanisms related to its antidepressant effects, the
inhibition of NMDARs is the most important. The observation
that NMDAR antagonists display antidepressant-like proper-
ties originates from the mid-90s and was first proposed by
Skolnick and coworkers at NIH (Skolnick et al. 1996;
Trullas and Skolnick 1990). However, other than KET, clini-
cally used uncompetitive NMDAR antagonists such as
memantine failed in clinical trials as antidepressants (Zarate
et al. 2006b). Another hypothesis involves KET metabolites
(Domino 2010), acting perhaps on other targets, likely involv-
ing AMPA receptors (Zanos et al. 2016). This area is also
controversial, because only norketamine (demonstrating de-
cent affinity at NMDARs, i.e., producing a 56% inhibition
of PCP binding sites at 10 μM) reduced immobility in the
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mouse forced swim test (FST), while dehydronorketamine
exhibited no antidepressant-like actions in mice and no sub-
stantial activity (12%) at NMDARs (Salat et al. 2015c).
KET (Krystal et al. 1994), like other uncompetitive
NMDAR antagonists (Morris and Wallach 2014), produces
profound PCP-like (Luby 1959) psychotomimetic effects in
humans including dissociative states, alterations in perception,
and schizophrenia-like positive and negative symptoms. From
this perspective, the failure of memantine to produce clinical
antidepressant effects (Zarate et al. 2006b) was likely due
either to insufficient dosing and/or to its micromolar affinity
at NMDARs which is lower than that of KET (Kornhuber
et al. 1991), and thus, the psychotomimetic effects are also
lower than those of KET. This hypothesis is at least partly
supported both by clinical findings showing that another
NR2B subunit-selective NMDAR antagonist, CP-101,606
(traxoprodil), also produced dissociative effects on top of an-
tidepressant actions in patients with MDD (Preskorn et al.
2008) and by studies on KET which revealed that the degree
of dissociative symptoms experienced during KET infusions
robustly correlated with the degree of reported depression rat-
ing scale improvement (Luckenbaugh et al. 2014). On the
other hand, GLYX-13 (rapastinel), a novel NMDAR
glycine-site functional partial agonist, produced an antidepres-
sant effect without psychotomimetic side effects typical for
NMDAR antagonists (Burgdorf et al. 2013; Moskal et al.
2014), which suggests that dissociative effects should not be
regarded as the only mechanism underlying antidepressant
activity observed in clinical settings.
While clinical trials are now being conducted with several
other than KET ligands of NMDARs (AXS-05, AVP-786,
Esketamine, CERC-301, GLYX-13; NRX-1074, AV-101;
(Murrough 2016)), in the present study, we focused on
tiletamine (TIL; 2-ethylamino-2-thiophen-2-yl-cyclohexan-
1-one), which is structurally and functionally similar to
KET. TIL is a use-dependent NMDAR antagonist (Rao et al.
1991; ffRench-Mullen et al. 1987) and an anesthetic tranquil-
izer used in veterinary medicine as a component of the product
named Telazol® or Zoletil® (tiletamine/zolazepam).
TIL was developed by Parke-Davis in the 1960s as an
alternative to KET and phencyclidine (PCP) (Chen et al.
1969). While it is currently contraindicated in patients, anec-
dotal reports indicate its KET-like or PCP-like properties. For
instance, at Erowid Experience Vaults (https://www.erowid.
org/pharms/t i letamine/) , anonymous psychonauts
(individuals who use mind-altered states to explore perceptual
and spiritual phenomena) have reported profound dissocia-
tive, psychotomimetic, and amnestic properties of Telazol,
much stronger than those of KET. Telazol has been reported
to produce less cardiovascular depression (c.f., Quail et al.
2001) than KET, which also shows urinary tract/bladder tox-
icity (c.f. Morris and Wallach 2014). The unique pharmacol-
ogy of TIL regarding dopaminergic system was studied by
Rao et al. (1991), who reported that in contrast to MK-801,
KET, and PCP, TIL did not increase pyriform cortex DOPAC
levels (i.e., did not increase DA metabolism and/or release),
suggesting some unique action not shared by other NMDAR
antagonists.
Other CNS-related properties of TIL are much less ex-
plored as compared to those of KET, and therefore knowledge
of its psychopharmacological profile is limited. In particular,
little is known about its potential antidepressant activity.
Hence, the main aim of this study was to compare the phar-
macological properties of TIL to those of KET in rodent
models. Because of its clinical (veterinary) use and established
safety, its psychoactive properties resembling KET’s dissocia-
tive states, and somewhat different from KET pharmacology,
we compared the behavioral properties of TIL to those of KET
in rodent tests of depression, anxiety, cognition, and negative-
like symptoms of psychoses. To interpret the results from
in vivo tests properly, we also investigated the influence of
TIL and KET on animals’ locomotor activity, pain threshold,
and potential motor deficits.
Materials and Methods
Animals
The study included adult male albino Swiss (CD-1) mice
weighing 18–22 g (Animal Breeding Farm of the
Jagiellonian University Faculty of Pharmacy, Poland) and
male Sprague-Dawley rats (Charles River, Germany),
weighing 200–250 g (novel object recognition test (NORT))
or 125–150 g (social interaction test) on arrival.
Mice were kept in groups of 10 in standard plastic cages
and housed under controlled conditions (room temperature of
22 ± 2 °C, light/dark (12:12) cycle, lights on at 8.00 a.m.,
humidity 50–60%, and free access to food and water). Rats
were housed in a temperature- (21 ± 1 °C) and humidity-
controlled (40–50%) colony room under a 12:12-h light/dark
cycle (lights on at 06:00 a.m.).
All experiments, except for sucrose preference tests, were
performed between 9 a.m. and 3 p.m. All procedures were
approved by the respective local ethics committees, and the
treatment of animals was in full accordance with ethical stan-
dards laid down in respective Polish and EU regulations
(Directive No. 86/609/EEC).
Chemicals
TIL hydrochloride (MedChemExpress, NJ, USA) was pre-
pared in 0.9% saline solution. KET (aqueous solution
(115.34 mg/ml), Vetoquinol Biowet, Gorzów Wielkopolski,
Poland) was diluted in distilled water to the appropriate con-
centrations. Drugs were administered intraperitoneally at a
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volume of 10 ml/kg (mice) and 1 ml/kg (rats), 30 min before
the behavioral tests. The doses of KET used in the present
research were chosen based on our previous studies
(Potasiewicz et al. 2017; Salat et al. 2015c) and available
literature data (Eskelund et al. 2017; Koike et al. 2011; Zhu
et al. 2017). Since there is a limited amount of data regarding
effective doses of TIL in rodents (Gargiulo et al. 2012; Su
et al. 2017), we conducted preliminary dose-response studies
(data not shown) to establish the starting dose of TIL (5 mg/kg
in mice and 0.5 mg/kg in rats).
Behavioral Procedures
Antidepressant-Like: Mouse Forced Swim Test
This experiment was carried out according to the method orig-
inally described by Porsolt et al. (1977) with some minor
modifications (Salat et al. 2015c). Mice were dropped individ-
ually into glass cylinders (height = 25 cm, diameter = 10 cm)
filled with water to a height of 10 cm and maintained at 23–
25 °C. The animals were left in the cylinder for 6 min. The
total duration of immobility was recorded during the final
4 min of the whole 6-min testing period. Mice were judged
to be immobile when they remained floating passively in the
water, making only small movements to keep their heads
above the water surface.
Antidepressant-Like (Anhedonia): Mouse Sucrose Preference
Test
Prior to the experiment, mice were placed into separate cages.
Two pre-weighed bottles, one containing tap water and the
other containing 1% sucrose solution, were placed on each
cage. The bottle order (left-right placement of water vs. su-
crose bottles) was counterbalanced amongmice in each group.
In this test, the mice were given a 48-h free choice between the
two bottles. At the beginning and the end of the test, the
bottles were weighed and consumption was calculated. The
test was begun with the onset of the dark (active) phase of the
animals’ cycle. The position of the bottles in the cage was
switched every 12 h. Before the test, no food or water depri-
vation was applied (Strekalova et al. 2004). The preference for
sucrose was calculated as a percentage of consumed sucrose
solution in terms of the total amount of liquid drunk.
Anxiety: Mouse Four-Plate Test
The four-plate apparatus (Bioseb, France) consists of a cage
(25 cm × 18 cm × 16 cm) that is floored with four rectangular
metal plates (11 cm × 8 cm). The plates are separated from one
another by a gap of 4 mm, and they are connected to an
electroshock generator. The test was performed according to
Bourin et al. (2005). After the habituation period (15 s), each
mouse was subjected to an electric shock (0.8mA, 0.5 s) when
crossing from one plate to another (two limbs on one plate and
two on another). The number of punished crossings was
counted during 60 s.
Anxiety (Obsessive-Compulsive Behavior), Depression,
Irritability and Impulsivity: Mouse Marble-Burying Test
The test was performed according to a method described by
Broekkamp et al. (1986), with some minor modifications.
Briefly, the mice were placed individually into plastic cages
identical to their home cages. The cages contained a 5-cm
layer of sawdust and 20 black glass marbles (1.5 cm diame-
ter), which were gently placed in the cage, equidistant in a
4 × 5 arrangement. After a 30-min testing period, the mice
were removed from the cages and the number of marbles at
least 2/3 buried was counted.
Cognition: Mouse Passive Avoidance Task
The test was conducted according to Salat et al. (2015b) using a
passive avoidance apparatus (Panlab Harvard Apparatus, Spain)
consisting of a large white-painted illuminated compartment
(26 × 26 × 34 cm) and a small black-painted dark compartment
(13 × 7.5 × 7.5 cm) separated from each other by a guillotine
gate. Mice underwent two separate trials, an acquisition trial
(conditioning phase) and a retention trial (testing phase), con-
ducted 24 h after the acquisition trial. For the acquisition trial,
each mouse was initially placed for 30 s in the light compart-
ment (exploration period; guillotine gate is closed). At the end of
the exploration period, the guillotine door (5 × 5 cm) was
opened and the time elapsed before entering the black chamber
was recorded. As soon as the mouse entered the dark compart-
ment, the door was automatically closed and an electrical shock
(current intensity = 0.2 mA, duration = 2 s) was delivered
through the grid floor. For the retention trial, the mice were
placed in the illuminated white compartment again, and the
latency time between door opening and entry into the dark com-
partment was recorded for each mouse up to 180 s (cutoff
latency).
Cognition: Rat Novel Object Recognition Test
The protocol described earlier (Nikiforuk et al. 2013a) was
adapted from the original work of Ennaceur and Delacour
(1988). At least 1 h before the start of the experiment, rats were
transferred to the experimental room for acclimation. Animals
were tested in a dimly lit (25 lx) open field apparatus made of a
dull gray plastic (66 × 56 × 30 cm). After each measurement,
the floor was cleaned and dried. The procedure consisted of a
5–min habituation to the arena without any objects, 24 h before
the test. The testing comprised two trials, separated by an inter-
trial interval (ITI) of 1 h. During the first (familiarization, T1)
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test period, two identical objects (A1 andA2) were presented in
opposite corners of the arena, approximately 10 cm from the
walls. Following T1, the objects were cleaned with water con-
taining a dishwashing agent and dried. In the second trial (rec-
ognition, T2), one of the objects was replaced by a novel one
(A = familiar and B = novel). Both trials lasted for 3 min. After
T1, animals were returned to their home cages. The objects
used were a 250-ml glass beaker (diameter of 8 cm, height of
14 cm) and a 250-ml plastic bottle (6 × 6 × 13 cm). The location
of the novel object in T2 was randomly assigned for each rat.
Exploration of an object was defined as rats looking, licking,
sniffing, or touching the object but not leaning against or stand-
ing or sitting on the object. Exploration time of the objects was
measured using the Any-maze® tracking system (Stoelting
Co., IL, USA). Based on the exploration time (E) of two ob-
jects, a discrimination index was calculated in accordance with
formula DI = (EB − EA) / (EA + EB), where EA is defined as
the time spent exploring the familiar object and EB is the time
spent exploring the novel object, respectively.
Negative Symptoms of Schizophrenia-Like Measure: Rat
Social Behavior
The experiments were conducted in an open field arena
(length × width × height = 57 × 67 × 30 cm) made of black
Plexiglas. The arena was dimly illuminated with an indirect
light of 18 lx. The behavior of the rats was recorded using
two cameras placed above the arena and connected to a
NoldusMPEG recorder 2.1. An experimenter blind to the treat-
ment conditions analyzed the videos off-line using Noldus
Observer®XT, version 10.5. The rats were individually housed
for 5 days prior to the start of the procedure. The animals were
subsequently handled and weighed, and the backsides of one
half of the animals were dyed with a gentian violet (2%
methylrosanilinium chloride) solution. On the test day (the
sixth day of social isolation), to reduce aggressive and territorial
behaviors and to increase the level of social behavior, two
unfamiliar rats of matched body weight (±5 g) were placed in
the open field arena, and their behaviors were recorded for
10 min. The social interaction time was measured for each rat
separately. The following active social behaviors were scored:
sniffing (the rat sniffs the body of the conspecific), anogenital
sniffing (the rat sniffs the anogenital region of the conspecific),
social grooming (the rat licks and chews the fur of the conspe-
cific), following (the rat moves toward and follows the other
rat), mounting (the rat stands on the back of the conspecific),
and climbing (the rat climbs over the back of the conspecific)
(Holuj et al. 2015). No overt aggressive behaviors (such as
biting, kicking, boxing, and threatening behavior) were ob-
served in control animals or after treatment with KET or TIL.
As the mean total time of aggressive behaviors was <3% of the
session duration, aggression was not included in the analysis.
The time of active social behaviors was summed to yield a total
score. As both animals in a pair yielded approximately equal
scores (for either total time spent in social interactions or sep-
arate social behaviors), social interaction time was expressed as
a summed score for each pair of animals.
In addition, we also measured the number of 50-kHz ultra-
sonic vocalizations (USVs) that accompany rat social interac-
tions and reflect a positive effect. This was done as described
earlier (Nikiforuk et al. 2013b).
Mouse Locomotor Activity
The locomotor activity test was performed as previously de-
scribed (Salat et al . 2015c) using activi ty cages
(40 cm × 40 cm × 30 cm) supplied with I.R. beam emitters
(Activity Cage 7441, Ugo Basile, Italy) connected to a counter
for the recording of light-beam interrupts. The animals’ move-
ments (i.e., the number of light-beam crossings) were counted
during the next 30 min of the test in 10-min time epochs.
Analgesia: Mouse Hot Plate Test
The hot plate apparatus (Hot/Cold Plate, Bioseb, France) con-
sists of an electrically heated surface and it is equipped with a
temperature controller that keeps the temperature constant at
55–56 °C. The test was performed as previously described
(Salat et al. 2015a). One day before the experiment, the ani-
mals were tested for their pain sensitivity threshold (baseline
latency). For further pain tests, only mice with baseline laten-
cies ≤30 s were selected. The latency time to pain reaction
(licking hind paws or jumping) wasmeasured as the indicative
of nociception. The cutoff time was established (60 s) and
animals that did not respond within 60 s were removed from
the hot plate apparatus and assigned a score of 60 s.
Motor Coordination: Mouse Rotarod Test
Before the test, mice were trained daily for three consecutive
days on a rotarod apparatus (May Commat RR0711, Turkey;
rod diameter = 2 cm) that was rotating at a fixed speed of
18 rpm. In each session, the mice were placed on the rotating
rod for 3 min with an unlimited number of trials. The proper
experiment was performed 24 h after the last training session
with the apparatus revolving at 6 or 24 rpm. Motor impair-
ments were defined as the inability to remain on the rotarod
apparatus for 1 min, and these were expressed as the mean
time spent on the rotarod (Salat et al. 2015a).
Statistics
Data were analyzed using one-way and/or two-way ANOVA
(IBM/SPSS 21 for Windows) with Dunnett’s post hoc test.
The alpha value was set at P < 0.05. The homogeneity of
variance was measured with Levene’s test.
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Results
Antidepressant-Like: Mouse Forced Swim Test
In the FST, two-way ANOVA demonstrated an overall effect
of treatment with KET (F(4, 51) = 4.64; P < 0.01). Time did
not affect the results (F(1, 51) = 1.38) and drug × time inter-
action was also insignificant (F(4, 51) = 2.44). For the sake of
curiosity, separate one-way ANOVAs were calculated on 30-
min post-treatment and 24-h post-treatment times, which
showed significant effects of the treatment at 30 min (F(4,
51) = 5.73; P < 0.001) but not at 24-h post-administration
(F(4, 51) = 2.19). Insignificant effects of KET 24-h post-
administration could have masked an apparent effect of 30-
min post-administration; indeed, at that time, KET reduced
immobility at doses of 10, 15, and 25 mg/kg (Fig. 1a).
For TIL, two-way ANOVA showed the following values:
drug effect (F(3, 28) = 3.41; P < 0.05), time effect (F(1,
28) = 21.91; P < 0.001), and drug × time interaction (F(3,
28) = 2.52). Again, separate one-way ANOVAs were calcu-
lated on two post-treatment times, which showed significant
effects of treatment at 30 min (F(3, 28) = 3.62; P < 0.05) but
not for the 24-h post-administration (F(3, 28) = 1.70). Again,
insignificant effects of TIL 24-h post-administration could
have masked an apparent effect of 30-min post-administra-
tion; indeed, at that time, TIL reduced immobility at the dose
of 10 mg/kg (Fig. 1b).
Antidepressant-Like (Anhedonia): Mouse Sucrose
Preference Test
In the sucrose preference assay, a significant effect of KET on
sucrose preference was demonstrated (F(4, 35) = 3.083,
P < 0.05; Fig. 1c), while TIL displayed no activity (F(3,
35) = 1.59; Fig. 1d).
Anxiety: Mouse Four-Plate Test
KET and TIL significantly affected the number of punished
crossings: F(4, 43) = 2.59 and P < 0.05 and F(3, 34) = 13.29
and P < 0.001, respectively.While TIL at doses of 5–15mg/kg
significantly increased the number of crossings (Fig. 2b), none
of theKET doses significantly affected the number of punished
crossings (Fig. 2a).
Anxiety (Obsessive-Compulsive Behavior), Depression,
Irritability, and Impulsivity: Mouse Marble-Burying Test
Statistical analyses showed the following ANOVA values:
F(4, 25) = 3.53 and P < 0.05 and F(3, 20) = 3.79 and
P < 0.05 for KET and TIL, respectively. KET significantly
reduced the number of buried marbles at the doses of 15–
25mg/kg (Fig. 2c); for TIL, only the dose of 15mg/kg exerted
a statistically significant effect (Fig. 2d).
Cognition: Mouse Passive Avoidance Task
In the passive avoidance task, two-way ANOVA demonstrat-
ed an overall effect of treatment with KET (F(4, 45) = 2.91;
P < 0.05). Time affected the results significantly (F(1,
45) = 102.95; P < 0.001) and drug × time interaction was also
significant (F(4, 45) = 3.21; P < 0.05). In the acquisition trial,
none of the KET doses affected entry latency in comparison
with the vehicle. However, in the retention trial, KET at doses
5 and 10 (but not 15 or 25) mg/kg significantly reduced the
latency to enter the dark compartment as compared with the
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vehicle, suggesting cognitive impairment produced by rela-
tively lower doses.
In the passive avoidance test, increased latency to reenter
the dark box serves as an index of learning. When latencies at
acquisition and retention trials were compared within a given
treatment, for the vehicle and all doses of KET, except for
5 mg/kg, retention latencies were longer than respective ac-
quisition latencies, suggesting somewhat unimpaired learning
except for only a KET dose of 5 mg/kg (Fig. 3a).
For TIL, two-way ANOVA showed the following values:
drug effect (F(3, 36) = 2.68; P = 0.06), time effect (F(1,
36) = 5.54; P < 0.05), and drug × time interaction (F(3,
36) = 18.83; P < 0.001. In the acquisition trial, TIL doses of
10 and 15mg/kg appeared to increase entry latencies, suggest-
ing potential sedative action or motor impairment. In the re-
tention trial, TIL at doses of 5–15 mg/kg reduced latencies to
enter the dark compartment, suggesting cognitive impairment.
When latencies in acquisition and retention trials were
compared within a given treatment, only for the vehicle-
treated group was retention latency longer than respective ac-
quisition latency. Only one dose of TIL (15 mg/kg) resulted in
a shorter retention than acquisition latency, suggesting learn-
ing deficit (Fig. 3b).
Cognition: Rat Novel Object Recognition Test
As shown in Fig. 3c, d, KET (10–20 mg/kg) and TIL (1–
2 mg/kg) disturbed NORT at relatively short ITI of 1 h: F(2,
26) = 26.86 and P < 0.001 and F(3, 28) = 16.95 and P < 0.001,
respectively.
In the same test, we measured the total time of either the
exploration of objects in the acquisition (T1) trial, purportedly
reflecting rats’ propensity to explore novel objects, or seda-
tion. While KET (Fig. 3e) did not affect this measure (F(2,
26) = 0.49), TIL (0.5 and 2 mg/kg; Fig. 3f) reduced it com-
pared to the vehicle (F(3, 28) = 4.82, P < 0.01).
Negative Symptoms of Schizophrenia-Like Measure: Rat
Social Behavior
Administration of KET (20 mg/kg) and TIL (2 mg/kg) reduced
total social interaction time compared to the vehicle-treated
animals (one-way ANOVA: F(5, 24) = 6.29; P < 0.001;
Fig. 4a) and the number of USVs emitted by the rats during
social encounters (F(5, 24) = 6.17; P < 0.001; Fig. 4b).
Mouse Locomotor Activity, Analgesia, and Motor
Coordination
An overall treatment effect of KET on locomotor activity was
observed (F(4, 35) = 3.82; P < 0.05). Time affected the results
significantly (F(2, 70) = 9.20; P < 0.001) and drug × time
interaction was also significant (F(8, 70) = 2.27; P < 0.05;
Fig. 5a). KET reduced activity at 25 (but not 5–15) mg/kg
and only within the first measurement epoch, i.e., up to
10 min following administration. For TIL, statistical analysis
showed the following ANOVA values: drug effect (F(3,
28) = 3.90; P < 0.05), time effect (F(2, 56) = 4.82;
P < 0.05), and drug × time interaction (F(6, 56) = 3.55;
P < 0.01; Fig. 5b). TIL at 10–15 mg/kg reduced activity at
the beginning of the measurement; the dose of 15 mg/kg also
reduced it up to 20 min following administration.
In the hot plate test, KET at doses of 5–25 mg/kg did not
demonstrate analgesic properties (F(4, 35) = 0.70; Fig. 5c).
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While for TIL, ANOVA yielded significant treatment differ-
ences (F(3, 36) = 3.0; P < 0.05; Fig. 5d) and none of the doses
produced significant alterations in pain reaction latency.
In the mouse rotarod test, the impact of KET and TIL on
motor coordination was assessed at 6 and 24 rpm separately
(Fig. 5e and f, respectively). For 6 rpm, ANOVAvalues were
F(7, 48) = 9.36 and P < 0.001 and for 24 rpm F(7, 48) = 7.05
and P < 0.001. At both speeds, KETat 25 and TIL at 15mg/kg
reduced motor coordination.
Discussion
The main goal of the present study was to assess potential
antidepressant-like properties of TIL and compare them to
those of KET. We also attempted to hypothesize as to which
tests could be indicative or useful in elucidating KET’s endur-
ing antidepressant-like effects. An unexpected finding of the
present study was that while KET produced behavioral effects
at doses comparable between species, in rats, TIL was ~10
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times more potent. At present, we cannot offer an explanation
for this finding; however, both compounds are antagonists at
NMDARs, with KET affinity of 119–1000 nM (see (Salat
et al. 2015c) and references therein). Our unpublished data
(A. Siwek) revealed that TIL Ki at [
3H]-MK-801 sites was
69 ± 14 nM (N = 3), which agrees with Rao et al. (1991) data
(IC50 at [
3H]-TCP labeled sites ~79 nM), suggesting that TIL
is six to eight times more potent than KET at NMDARs.
The results of the present in vivo study are summarized in
Table 1 that shows that while KET and TIL produced
antidepressant-like action in the mouse FST and anti-
obsessive-compulsive effect in marble-burying test, they also
reduced locomotor activity and disturbed learning processes.
The reduction of locomotor activity indicates the specific
anti-immobility effect in the FST, because stimulant effects
are regarded as unspecific. However, the antidepressant-like
activity of TIL in FST was not stronger than that of KET, and
TIL reduced immobility at only one - (mid-) dose, whereas
KET was effective at doses 10–25 mg/kg. Moreover, investi-
gating behaviorally naive mice, we noted no enduring
antidepressant-like effects of KET and TIL in FST, which
agrees with previous reports (Bechtholt-Gompf et al. 2011;
Popik et al. 2008). This confirms that the Bnormal^ mouse
FST is not suitable and sensitive enough to detect persistent
antidepressant-like effects of KET and that animal models of
depression such as rat chronic mild stress (Papp et al. 2017) and
mouse chronic social defeat stress and lipopolysaccharide-
induced depression-like phenotypes (Yang et al. 2017) are
more appropriate. The limitation of the present experiments
was the lack of a time-course study.
KET at the lowest dose tested (5 mg/kg) unexpectedly re-
duced sucrose preference, i.e., it augmented anhedonia,
whereas the treatment with TIL did not influence sucrose in-
take at any of the doses used. The sucrose preference test is a
reward-based assay used to detect anhedonia-like state in ro-
dents (Strekalova et al. 2004; Papp et al. 2017). The results
obtained for KET appear to contradict those reported by Papp
et al. (2017) and Yang et al. (2017), who, however, investigat-
ed the effect of KET in animal models of depression, while we
used naive mice. Also, in the Papp et al. study, KET did not
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affect sucrose intake in non-stressed controls (Papp et al.
2017).
Examination of dissociative-like effects revealed that both
compounds disturbed social behavior and reduced 50-kHz
USVemission in rats. Of note was the fact that in both assays
for KET, this effect reached statistical significance at a dose
10-fold higher than that for TIL (20 vs. 2 mg/kg).
Investigation of the Bside effects^ demonstrated that only at
the highest doses did both compounds produce motor deficits
in the rotarod test. In addition, neither KET nor TIL affected
pain response in the hot plate test. This acute pain model was
used as a control for the passive avoidance and four-plate tests,
and it enabled the exclusion of potential false positive results
in these two assays.
Using a preliminary assay based on the unconditioned fear
model of anxiety, i.e., the four-plate test, we also investigated
if KET or TIL could have anxiolytic-like properties in mice.
This test revealed that TIL, in contrast to KET, possessed
additional anxiolytic-like properties. These results should be
taken with care, as we implemented only one behavioral test
and further extended research is required to confirm this
activity of TIL in other tests, such as the elevated plus maze
which is based on the natural aversion of mice for open and
elevated areas and on their natural spontaneous exploratory
behavior in novel environments. Hayase et al. (2006) reported
no effects of KET in the elevated plus maze test in ICR mice,
while Silvestre et al. (1997) used three non-conflict tests
(holeboard, social interaction, and elevated plus maze para-
digms) and observed (a) decreased time spent in the active
social interaction, (b) decreased percentage of time spent in
open arms of the elevated plus maze, and (c) no significant
effect on head dipping in the holeboard test. These authors
suggested an anxiogenic-like effect of KET that contrasted
with the effects produced by other uncompetitive NMDAR
antagonists and resembled those described for stimulant drugs
such as caffeine, cocaine, or amphetamine. While we used a
different (four-plate) test, our data agree with the above, in that
KET displays no anxiolytic-like actions. However, TIL in-
creased the number of punished crossings in the four-plate test
and this effect appeared specific, as this drug did not increase
animals’ locomotor activity.
Themarble-burying behavior, similarly to the four-plate test,
comprises many kinds of domains related to anxiety, so it can
be interpreted in various ways. Firstly, marble-burying has been
suggested to reflect a form of impulsive behavior (Gyertyan
1995), and has even been regarded as a model of obsessive-
compulsive disorder (Borsini et al. 2002; Njung'e and Handley
1991; Broekkamp et al. 1986; Li et al. 2006) in which the
majority of antidepressants are effective in the attenuation of
symptoms (reviewed by Borsini et al. 2002; Ammar et al.
2015). Acute administration of selective serotonin reuptake in-
hibitors, tricyclic antidepressants, selective noradrenaline reup-
take inhibitors, and dual noradrenaline/serotonin reuptake in-
hibitors selectively and dose-dependently suppressed marble-
burying behavior in mice (Schneider and Popik 2007;
Marinova et al. 2017; Rodriguez et al. 2013). Secondly, the
suppression of spontaneous burying of harmless objects by
rodents is known to be sensitive to anxiolytic drugs rather than
antipsychotics (Broekkamp et al. 1986; Njung'e and Handley
1991). Recently, a positive effect of memantine as an augmen-
tation therapy for obsessive-compulsive disorder has been
demonstrated (Marinova et al. 2017). KET is effective in pa-
tients with treatment-resistant depression, obsessive-
compulsive disorder, and post-traumatic stress disorder (Glue
et al. 2017; Rodriguez et al. 2013). This rapid anti-obsessive-
compulsive effect achieved after a single intravenous dose of
KET persisted for at least 1 week (Rodriguez et al. 2013). Our
findings are in line with those mentioned above, as both KET
Table 1 Summary of behavioral effects of ketamine (KET) and tiletamine (TIL) in mice and rats
Test Species KET active dose(s) TIL active dose(s) Figure
Immobility in FST (antidepressant-like) Mouse 10–25 (↓) 10 (↓) Figure 1a, b
Sucrose preference (antidepressant-like, anhedonia) Mouse 10 (↓) – Figure 1c, d
Four-plate (anxiolytic-like) Mouse – 5–15 (↑) Figure 2a, b
Marble-burying (anxiolytic-like, obsessive-compulsive
behavior antidepressant-like, irritation, and/or perseveration)
Mouse 15–25 (↓) 15 (↓) Figure 2c, d
Latency to enter dark compartment in passive avoidance
(cognition)
Mouse 5,10 (↓) 5–15 (↓) Figure 3a, b
Novel object recognition (cognition) Rat 10–20 (↓) 1–2 (↓) Figure 3c, d
Novel object recognition (exploration) Rat – 0.5, 2 (↓) Figure 3e, f
Social interaction and 50-kHz USVemission (social withdrawal,
negative-like symptoms of schizophrenia, psychotomimetic-like)
Rat 20 (↓) 2 (↓) Figure 4a, b
Locomotor activity Mouse 25 (↓) 10–15 (↓) Figure 5a, b
Hot plate (antinociceptive action) Mouse – – Figure 5c, d
Motor coordination in rotarod Mouse 25 (↓) 15 (↓) Figure 5e, f
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and TIL significantly reduced marble-burying behavior at a
comparable dose of 15 mg/kg. However, the analysis of both
the four-plate test’s and marble-burying test’s results indicates
the superiority of TIL over KET in anxiety-spectrum disorders.
The analysis of social behaviors of pairs of unfamiliar rats
represents an ethologically valid approach for the preclinical
assessment of social functions (Sams-Dodd 2013) and in some
settings, not used in the present study (unfamiliar environment
and high level of lights), serves to measure anxiety. NMDAR
antagonists (Koros et al. 2007), including KET (Nikiforuk
et al. 2013b), are capable of modeling negative-like symptoms
of psychoses expressed as a social withdrawal. The present
data are consistent with these findings, in that both KET and
TIL reduced the time spent in active social interactions. In
addition, we showed that both compounds reduced 50-kHz
ultrasonic Bhappy^ calls that accompany social behavior
(Nikiforuk et al. 2013b). Such effects have been interpreted
as being indicative for psychotomimetic actions, that is, hal-
lucinations and delusions (Sams-Dodd 2013). In the context
of enduring antidepressant actions of KET (Zarate et al.
2006a; Berman et al. 2000), we do not view these data as
Bundesired side^ effects, particularly in light of the reports
presented in the BIntroduction^ section (Griffiths et al. 2016).
Both the passive avoidance test in mice and the novel ob-
ject recognition test in rats demonstrated amnestic actions of
KETand TIL.While NMDAR antagonists impaired cognitive
processes in naive subjects, KET displays pro-cognitive ef-
fects in stressed or Bdepressed^ rats (Nikiforuk and Popik
2014; Papp et al. 2017). Nonetheless, these data further sug-
gest that both compounds could have dissociative-like effects
reflecting disturbed attention of animals.
Using the hot plate test (i.e., the thermally induced pain
model), we examined whether purported analgesic properties
of KET or TIL could have contributed to the amnestic effects
observed in the passive avoidance task and anxiolytic-like ac-
tion in the four-plate test. However, the present data agree with
earlier reports (Plesan et al. 1998) and demonstrate no changes
in heat pain thresholds after treatment with KET and TIL.
In summary, antidepressant-like properties of both KET
and TIL, as well as their adverse effect liabilities, are similar.
TIL has an additional anxiolytic-like profile. The present data
demonstrate the usefulness of animal research in finding the
dissociative-like states in preclinical settings purportedly nec-
essary for the enduring antidepressant effects of noncompeti-
tive NMDAR antagonists.
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